Combined with our published data in RA, our current findings reveal that anti-PAD2 antibodies, present in a subset of individuals, associate with less severe symptoms in diseases united by high PADI2 expression in the target tissue (i.e. the synovium in RA and the CNS in MS and PTLD). Here, PADI2 is linked to myeloid sarcoma.